FiercePharma13h
Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Patients using diabetes apps can miss critical alerts. Here’s how to make sure you’re getting them
Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications ...